Drugs / SP0202-III
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06698198 | Dec 2018 → Sep 2019 | idiopathic severe pneumococcemia | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP0202-III | “Group 3: Pneumococcal Conjugate Vaccine (PCV) SP0202-III” NCT06698198 ↗ |
| Route | Intramuscular | “1 intramuscular injection of PCV formulation SP0202-III” NCT06698198 ↗ |